A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.
作者信息
Clancy Cornelius J, Nguyen M Hong
机构信息
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa617. doi: 10.1093/ofid/ofaa617. eCollection 2021 Feb.
Abstract
摘要
相似文献
1
A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.《2019冠状病毒病治疗史初稿：美国医院中旧药新用情况》
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa617. doi: 10.1093/ofid/ofaa617. eCollection 2021 Feb.
2
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.2020年3月至5月美国医院中用于2019冠状病毒病的药物的真实世界住院使用情况
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa616. doi: 10.1093/ofid/ofaa616. eCollection 2021 Feb.
3
Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group.2019冠状病毒病患者中重新利用药物使用情况的差异。来自危重病医学学会发现病毒感染与呼吸道疾病通用研究：2019冠状病毒病登记研究者小组。
Crit Care Explor. 2021 Nov 2;3(11):e0566. doi: 10.1097/CCE.0000000000000566. eCollection 2021 Nov.
4
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病（COVID-19）后成年人暴露者预防严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的暴露后预防效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
5
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
6
Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.某些 COVID-19 再利用药物致药物性长 QT 综合征的风险评估。
Clin Transl Sci. 2021 Jan;14(1):20-28. doi: 10.1111/cts.12882. Epub 2020 Nov 18.
7
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.抗 SARS-CoV-2 感染的 FDA 批准药物在雪貂中的抗病毒疗效。
mBio. 2020 May 22;11(3):e01114-20. doi: 10.1128/mBio.01114-20.
8
COVID-19: Therapeutics and Their Toxicities.新型冠状病毒肺炎（COVID-19）：治疗药物及其毒性。
J Med Toxicol. 2020 Jul;16(3):284-294. doi: 10.1007/s13181-020-00777-5. Epub 2020 Apr 30.
9
Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.为COVID-19大流行早期住院患者的药物再利用治疗指南提供信息的临床证据：皮质类固醇、抗凝剂、（羟）氯喹
Front Public Health. 2022 Feb 18;10:804404. doi: 10.3389/fpubh.2022.804404. eCollection 2022.
10
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病（NO COVID-19）实用开放性标签研究，评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
引用本文的文献
1
Understanding uptake of information about innovations among emergency department clinicians during the COVID-19 pandemic.了解新冠疫情期间急诊科临床医生对创新信息的接受情况。
J Am Coll Emerg Physicians Open. 2024 Jul 19;5(4):e13243. doi: 10.1002/emp2.13243. eCollection 2024 Aug.
2
Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.扎普诺替尼治疗COVID-19住院成年患者的疗效和安全性（RESPIRE）：一项随机、双盲、安慰剂对照、多中心、概念验证的2期试验。
EClinicalMedicine. 2023 Oct 4;65:102237. doi: 10.1016/j.eclinm.2023.102237. eCollection 2023 Nov.
3
Incidence and Predictors of COVID-19 Infection in Prison Healthcare Workers.监狱医护人员中 COVID-19 感染的发生率及预测因素。
J Occup Environ Med. 2023 Jul 1;65(7):573-579. doi: 10.1097/JOM.0000000000002836. Epub 2023 Mar 7.
4
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.门诊使用羟氯喹治疗轻症 COVID-19 患者的临床结局。
Int Immunopharmacol. 2021 Jul;96:107636. doi: 10.1016/j.intimp.2021.107636. Epub 2021 Apr 6.
本文引用的文献
1
PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates.正方观点：新冠疫情将导致抗菌药物耐药率上升。
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa049. doi: 10.1093/jacamr/dlaa049. Epub 2020 Jul 17.
2
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.2020年3月至5月美国医院中用于2019冠状病毒病的药物的真实世界住院使用情况
Open Forum Infect Dis. 2020 Dec 15;8(2):ofaa616. doi: 10.1093/ofid/ofaa616. eCollection 2021 Feb.
3
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.2020年3月1日至6月30日期间，通过美国2019冠状病毒病相关住院监测网络确定的住院患者中正在使用的COVID-19研究性治疗方法。
Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
4
Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.大剂量阿奇霉素分发与大环内酯类和非大环内酯类耐药性。
N Engl J Med. 2020 Nov 12;383(20):1941-1950. doi: 10.1056/NEJMoa2002606.
5
Trends in COVID-19 Risk-Adjusted Mortality Rates.COVID-19 风险调整死亡率趋势。
J Hosp Med. 2021 Feb;16(2):90-92. doi: 10.12788/jhm.3552.
6
The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days.全球应对 COVID-19 大流行的临床试验研究——前 100 天
F1000Res. 2020 Oct 2;9:1193. doi: 10.12688/f1000research.26707.2. eCollection 2020.
7
Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.羟氯喹和氯喹的处方模式按医生专业划分，参考了最初关于其对 COVID-19 治疗潜在益处的报告 - 美国，2020 年 1 月至 6 月。
MMWR Morb Mortal Wkly Rep. 2020 Sep 4;69(35):1210-1215. doi: 10.15585/mmwr.mm6935a4.
8
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.羟考酮治疗对严重 COVID-19 患者死亡率和器官支持的影响：REMAP-CAP COVID-19 皮质类固醇随机临床试验。
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
9
Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter.一家地处新冠疫情早期震中之外的医院的抗生素使用与管理
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01011-20.
10
Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area.休斯顿都会区初始高峰期和复燃期间 COVID-19 患者的特征和结局。
JAMA. 2020 Sep 8;324(10):998-1000. doi: 10.1001/jama.2020.15301.
Zotero 插件